Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo

BACKGROUND/AIMS: The success of sorafenib in the treatment of advanced hepatocellular carcinoma (HCC) has focused interest on the role of Ras signaling in this malignancy. We investigated the molecular alterations of the Ras pathway in HCC and the antineoplastic effects of sorafenib in combination w...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Newell, Pippa, Toffanin, Sara, Villanueva, Augusto, Chiang, Derek Y., Minguez, Beatriz, Cabellos, Laia, Savic, Radoslav, Hoshida, Yujin, Lim, Kiat Hon, Melgar-Lesmes, Pedro, Yea, Steven, Peix, Judit, Deniz, Kemal, Fiel, M. Isabel, Thung, Swan, Alsinet, Clara, Tovar, Victoria, Mazzaferro, Vincenzo, Bruix, Jordi, Roayaie, Sasan, Schwartz, Myron, Friedman, Scott L., Llovet, Josep M.
Format: Artigo
Idioma:Inglês
Publicat: 2009
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2970800/
https://ncbi.nlm.nih.gov/pubmed/19665249
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jhep.2009.03.028
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars